



ASX ANNOUNCEMENT

16 MAY 2024

PHASE 1B STUDY OF CHM CORE-NK + VACTOSERTIB RE-OPENS FOR ENROLMENT

Sydney, Australia, 16 May 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce that the investigator-sponsored Phase 1B study of CHM CORE-NK plus vactosertib has re-opened for enrolment.

CHM CORE-NK is a universal off-the-shelf NK cell therapy manufactured with the CORE-NK platform, which can produce hundreds of doses in a single manufacturing run. CHM CORE-NK was previously studied in a Phase 1 clinical trial that established safety with no GvHD (Graft versus Host Disease), prolonged NK cell persistence at 28 days, and an encouraging early efficacy signal, particularly in blood cancers where all patients achieved disease control. One patient achieved a complete response that was sustained for over 15 months at time of study publication.

The Phase 1B study (NCT05400122) is intended to build upon the clinical responses seen in the initial CHM CORE-NK Phase 1A clinical trial by adding vactosertib, an oral TGF- β receptor inhibitor that can potentially disrupt the TGF- β signalling pathway. The study is designed to treat 12 patients with either locally advanced/metastatic colorectal cancer or relapsed/refractory blood cancers.

Enrolment in the study reopened this week, following a temporary interruption in December 2023 due to site-related resourcing constraints.

“We are very happy that this study has reopened, and we look forward to advancing this exciting new cell therapy combination for cancer patients” said Dr Rebecca McQualter, Chief Operating Officer of Chimeric.

The Phase 1B trial is currently funded without financial support from Chimeric Therapeutics.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.



Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 current clinical programs and plans to open additional clinical programs in 2024.

CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM CLTX is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM CDH17 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer. CHM CDH17 is currently in preclinical development with a planned phase 1A clinical trial in gastrointestinal and neuroendocrine tumours in 2024.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CHM CORE-NK in combination regimens have been initiated. From the CHM CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors

Dr Rebecca McQualter
Chief Operating Officer
Chimeric Therapeutics
T: + 61 498 966 180
E: RMcQualter@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au